Vytorin And Zetia Draw Suits And Scrutiny

Law360, New York (January 16, 2008, 12:00 AM EST) -- The stakes are high for Merck & Co. and Schering-Plough Corp. as they face proposed class actions and a congressional inquiry over doubts of the effectiveness of their cholesterol drugs, Vytorin and Zetia, which account for a whopping $5 billion in annual sales.

At least two proposed class actions filed Thursday are going after the drug manufacturers’ hefty profits, seeking monetary and other damages from the drug companies for allegedly breaking state consumer protection laws in their sale and marketing of the drugs.

Two House representatives...
To view the full article, register now.